📝 2024 MILESTONES At Syntropic, 2024 has been a transformative year. A remarkable journey of growth and achievements that began only in January 2024: 🎯 Secured fundings from xista science ventures, with additional support from Austria Wirtschaftsservice and FFG Austrian Research Promotion Agency to drive ongoing research and development. 🌍 Graduated from Creative Destruction Lab and invited to the CDL Super Session in Toronto this summer, putting Syntropic on the global stage. 🏆 Shortlisted among the Top 12 Health Techpreneurs in the Innovation World Cup at MEDICA - Leading International Trade Fair and the Deep Tech Pioneers at Hello Tomorrow over 4,600 international submissions from 120 countries. 🧠 Advanced our research and clinical development, collecting promising successful data on the technology's safety and tolerability. 🌟 Assembled an outstanding Board of Advisors, to be announced soon. None of this would have been possible without the support of our exceptional growing team: Maria Teresa Ferretti (Clinical Development Lead), Amin Alam (R&D Engineer), Frieda Leesch (Research Associate), Francesca Giovanetti (Founder's Associate), and Federica Montrone (Medical Device Engineer). We are proud of how far we’ve come and excited for what lies ahead. Here’s to innovation, perseverance, and the incredible journey forward in 2025! #neurotech #mentalhealth #innovation #startupjourney
Syntropic
Herstellung medizinischer Geräte
Syntropic develops novel new treatments for psychiatric disorders.
Info
Syntropic is a clinical stage medical device company developing new technologies that enhance the brain’s neuroplasticity, allowing for the treatment of psychiatric disorders and the improvement of cognition.
- Website
-
www.syntropicmedical.com
Externer Link zu Syntropic
- Branche
- Herstellung medizinischer Geräte
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Vienna
- Art
- Privatunternehmen
- Gegründet
- 2023
Orte
-
Primär
Wegbeschreibung
Vienna, AT
Beschäftigte von Syntropic
-
Alessandro Venturino
Neuroscientist @ ISTAustria | Founder of Syntropic Medical GmbH | MedTech entrepreneur.
-
Maria Teresa Ferretti
Neuroscience - Brain health- Gender Medicine - Consultant- TED-x Speaker - Scientific Writer -Alzheimer Advocate - Editor -Privat Dozent - FEAN
-
Federica Montrone
Biomedical Engineer in Neurotech
-
Amin Alam
Computer Scientist and Engineer
Updates
-
🎄 Wishing you a Merry Christmas and Happy Holidays! From all of us at Syntropic thank you for being part of our journey this year. See you in 2025! #HappyHolidays #MerryChristmas #Syntropic
-
-
👥 Introducing our Founders & Team series! Next up: Sandra Dr. Siegert, Co-founder and Scientific Advisor. Sandra’s groundbreaking research on microglia and brain function laid the foundation for Syntropic’s journey. Stay tuned to meet the rest of the team! Link in the comment below 👇 #MeatTheTeam #StartupJourney #Innovation
-
-
🗞️ NEWS "With Light Against Inner Darkness" Depression impacts millions worldwide, yet current therapies remain limited, often relying on decades-old pharmacological solutions. That’s where Syntropic steps in, offering a groundbreaking non-invasive, non-pharmacological light therapy based on cutting-edge research into brain plasticity and microglia activation. 📖 Read the full story on #LaborJournal in the first comment! #mentalhealth #depression #neurotech #lightherapy
-
-
👥 Introducing our Founders & Team series! Next up: Jack O'Keeffe, our Co-Founder & CTO Jack brings deep expertise in design control and product development, essential to advancing our technology with precision and purpose. Stay tuned to meet the rest of the team! Link in the comment below 👇 #MeatTheTeam #StartupJourney #Innovation
-
-
🔬 SCIENCE Explore the #neuroplasticity theory behind depression and discover how Syntropic is harnessing this science to make a difference. #neuroplasticity #research #depression #neurostimulation
Neuroscience - Brain health- Gender Medicine - Consultant- TED-x Speaker - Scientific Writer -Alzheimer Advocate - Editor -Privat Dozent - FEAN
´Modulating neuroplasticity to treat depression – bringing innovation to patients´ Last week, in Berlin, I joined Prof. Dr. Claus Normann, Christoph Nissen, Stefan Vestring, and Prof Volker Coenen in this very interesting symposium at the dgppn - Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde conference (the meeting of the German psychiatry society with over 9K people attending). Why neuroplasticity and depression? According to the neuroplasticity hypothesis, depression can be conceptualized as an inflexibility of cognitive and emotional brain circuits, leading to persistent negative bias. Markers of neuroplasticity are consistently downregulated in depression, and all treatments shown to be effective in relieving symptoms (from SSRIs to ECT) do increase neuroplasticity. Ketamine and serotonin psychedelics are well known to promote structural and functional neuroplasticity. But are there other ways to modulate neuroplasticity which we could explore clinically? Well, this symposium clearly showed that this field is very active and promising. 💊 Prof Vestring described the development of a novel small molecule, called NAB-14, which is a GluN2D antagonist (similar to ketamine but cleaner). In preclinical models this molecule was effective in increasing plasticity and LTP. 😴 Prof Nissan is leveraging a well-known effect of sleep deprivation on synaptic homeostasis to treat depression. The team has developed a ´sleep cap´ to selectively suppress slow waves during sleep without awakening the patient. 🧠 Prof Coenen described a minimally invasive electrode for epicranial stimulation. If successful this could become an implantable alternative to rTMS protocols such as SAINT. 💡 Yours truly presented the foundation of the work we do at Syntropic - the discovery of the effect of 60Hz intermittent light on perineuronal nets and plasticity. Light stimulation might become a non invasive novel approach for neuromodulation, just stay tuned. I find it fascinating that as the field is exploring new ways to treat depression (with neurostimulation and psychedelics, for instance), in the process it is also reconsidering the understanding of depression itself (well beyond the chemical imbalance). Exciting times and much to discover! Thanks to prof Normann for leading this symposium and inviting us; to coauthors Alessandro Venturino, Amin Alam and Sandra Dr. Siegert and the whole team at Syntropic for the great work together.
-
-
If you are attending the annual dgppn - Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde in Berlin, don’t forget to ping our Maria Teresa Ferretti today!
Neuroscience - Brain health- Gender Medicine - Consultant- TED-x Speaker - Scientific Writer -Alzheimer Advocate - Editor -Privat Dozent - FEAN
I am in Berlin, representing Syntropic at the annual DGPPN meeting (Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde, expecting over 9000 specialists in the field of psychiatry). Excited to have this opportunity to share our results with the scientific community. If you are attending, pass by tomorrow in room A2 at 8.30am. We will be talking about neuroplasticity, brain entrainment, and how to bring innovation to patients with #depression.
-
-
👥 Introducing our Founders & Team series! Next up: Mark Caffrey, our Co-Founder & CEO. From leading Medtech innovations to founding his first Neurotech startup, Mark’s journey fuels our mission to make mental health solutions more effective. https://lnkd.in/dKnuK2Kj Stay tuned to meet the rest of the team! #MeatTheTeam #StartupJourney #Innovation
-
🗞️ NEWS Exciting update! Prof. Sandra Dr. Siegert, our co-founder, is featured in #NewsWissenschaft for our innovative 60-Hz light therapy, a non-invasive approach to treating depression. 🔬 At ISTA Klosterneuburg, Prof. Siegert’s research explores the critical role of microglia—immune cells in the brain—in reshaping neural connections. This breakthrough has paved the way for a novel, science-driven therapy for mental health disorders. 💡 The highlight? A 60-Hz light-therapy device, offering an accessible and non-invasive alternative to traditional treatments. Early results are promising, with the potential to transform mental health care for millions. Discover more: https://lnkd.in/dKT6Z9rZ #MentalHealth #DepressionTreatment #SyntropicMedical #Neurotech #ISTA #NEWS
New therapeutic approach for depression - Syntropic Medical
https://syntropicmedical.com
-
🏅 AWARD Exciting news! Syntropic Medical has been named a #DeepTechPioneer by Hello Tomorrow out of 4,600 global applicants from 120 countries. What started as a scientific discovery in the lab just a year ago, has now evolved into a tangible prototype. It’s incredibly exciting to see our technology gain international recognition! We’re incredibly grateful to our dedicated team and advisors, for making this milestone possible. Here’s to making a lasting impact! #deeptech #mentalhealth #neurotech #hellobetter
-